Bryleos jobs and careers

About Bryleos

Early clinical stage therapeutics company developing BRY101, a metabolic modulator engineered to increase intracellular NAD, impacting mitochondrial dysfunction, neuroinflammation and oxidative stress. BRY101 impacts multiple pathways simultaneously, breaking away from the traditional single-target drug development model. This strategy is designed to address the complex mechanisms involved in neurodegenerative and neuromuscular disorders. Bryleos: More Life While Living

Founded in 2021 by Wendy Komac.